avagacestat (BMS-708163) / BMS |
NCT01454115: Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163 |
|
|
| Completed | 1 | 116 | US | BMS-708163 (Gamma-Secretase Inhibitor), Placebo matching BMS-708163 | Bristol-Myers Squibb | Alzheimer's Disease | 03/09 | 03/09 | | |
|
NCT00860275: Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole |
|
|
| Completed | 1 | 30 | US | BMS-708163, BMS-708163 + Ketoconazole, Ketoconazole, Fluconazole, BMS-708163 + Fluconazole | Bristol-Myers Squibb | Alzheimer Disease | 06/09 | 06/09 | | |
NCT00901498: Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease |
|
|
| Completed | 1 | 36 | US | BMS-708163 | Bristol-Myers Squibb | Alzheimer's Disease, Healthy | 07/09 | 07/09 | | |
NCT00979316: Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects |
|
|
| Completed | 1 | 62 | US | BMS-708163, Placebo, Moxifloxacin, Avelox | Bristol-Myers Squibb | Alzheimer Disease | 02/10 | 02/10 | | |
NCT01039194: Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER) |
|
|
| Completed | 1 | 18 | US | galantamine, Razadyne ER ™, BMS-708163 | Bristol-Myers Squibb | Alzheimer Disease | 04/10 | 04/10 | | |
|
NCT01042314: Drug-Drug Interaction Study With Aricept® (Donepezil) |
|
|
| Completed | 1 | 18 | US | Donepezil, Aricept®, BMS-708163 | Bristol-Myers Squibb | Alzheimer Disease | 04/10 | 04/10 | | |
|
| Completed | 1 | 22 | US | BMS-708163, (GAMMA SECRETASE inhibitor), Placebo | Bristol-Myers Squibb | Alzheimer Disease | 06/10 | 06/10 | | |
|
| Completed | 1 | 20 | RoW | BMS-708163, Rifampin | Bristol-Myers Squibb, PRA Health Sciences | Alzheimer Disease | 10/10 | 10/10 | | |
NCT01079819: Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163 |
|
|
| Completed | 1 | 32 | US | BMS-708163, Placebo | Bristol-Myers Squibb | Alzheimer's Disease | 12/10 | 12/10 | | |
|